- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
PMCPA case summary: Head of Medicines Optimisation complaint against GlaxoSmithKline. The provided case text contains no details of the allegations, clauses, outcome…
BMS’ Sprycel CML leavepiece used mechanism-of-action and potency/mutation claims without making clear they were in vitro or clinically relevant. Panel found multiple…
Anonymous physician alleged Santen staff pressured delegates to leave a poster session for a company symposium and used hospitality as an inducement.…
A doctor complained Astellas reps sought 4 visits between mid-Oct and Christmas. PMCPA found the briefing encouraged excessive calling and treated the…
Takeda challenged Daiichi-Sankyo’s Olmetec materials comparing olmesartan 20mg with candesartan 8mg and use of a reprint with outdated candesartan dosing. Leavepiece and…
Complaint alleged advertising of an unlicensed medicine. PMCPA recorded no breach because the matter was outwith the scope of the Code. Undertaking…
Complaint about promotion of Fostair. PMCPA recorded no breach because the matter was outwith the scope of the Code. Undertaking received.
Alexion UK employees ‘liked’ a US LinkedIn post linking to a press release about ALXN1210. The Panel said ‘liking’ proactively disseminated it…
Complaint alleged Sanofi-sponsored meeting adverts on Facebook/Twitter lacked sponsorship statements and reached the public. Sanofi said it did not sponsor the meetings;…
PMCPA case AUTH/2909/11/16 (Director v Astellas UK) concerning clinical trial disclosure for Xtandi. Outcome: no breach; matter found outwith the scope of…
PMCPA found Ilumetri website headline claims on dosing, efficacy and QoL misleading/unsupported (Clauses 7.2, 7.4) and ruled high standards/digital requirements breached (9.1,…
Complaint alleged Novo Nordisk regional medical advisors acted promotionally and pressured reps to secure meetings/targets. Panel found complainant provided insufficient evidence; no…
Anonymous UK health professional complained Avamys banner ad on Pulse had an illegible generic name. Panel found breaches of Clauses 4.3 and…
Takeda materials for Prostap hosted on Guidelines in Practice were ruled unclear about which formulation was licensed for ovarian function preservation. Breaches…
A UK health professional challenged an Octasa 1600mg journal ad for “Always once-daily” and imagery suggesting under-18 use. The PMCPA Panel found…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.